American Society of Clinical Oncology (ASCO)
Futu Unveils Major AI Upgrade, Making Professional Agentic Investing Accessible to All, Seize the Next Rally with FUTU AI
HONG KONG, July 16, 2026 /PRNewswire/ -- Futu Securities International (Hong Kong) Limited ("Futu") announced a comprehensive upgrade to its AI capabilities with the launch of "Expert" mode, its self-developed and built-in AI agent. Powered by a novel "Agentic AI + Skills" architecture that deli...
Kelun-Biotech Announces Phase III Study of Sacituzumab Tirumotecan (sac-TMT) in Combination with Pembrolizumab as First-Line Treatment for PD-L1-Negative Non-Squamous NSCLC Met Primary Endpoint
* As a head-to-head Phase III trial comparing sac-TMT plus pembrolizumab with the first-line standard of care (immunotherapy plus chemotherapy), OptiTROP-Lung06 demonstrated the superiority of replacing conventional pemetrexed/platinum chemotherapy with sac-TMT, with significantly prolonged PFS...
Gene Solutions' SPOT-MAS 10 Places Asia-Led Cancer Screening Innovation in the Global Spotlight
A blood-based cancer screening technology developed in Asia is gaining international attention after real-world data from more than 84,145 individuals were presented at ASCO Breakthrough 2026 and highlighted by the American Society of Clinical Oncology. For Gene Solutions, this milestone under...
Dx&Vx (DXVX) Partners with Over 40 Global Companies at BIO USA, "Focused Discussions on Overseas Out-Licensing Deals"
* Oral obesity drug with world-first mechanism of action unveiled, drawing strong on-site interest * Following successful Phase 1 clinical results, global discussions on OVM-200 expand * Meetings with over 40 companies, including major pharmaceutical companies, out-licensing now within reac...
Fox ESS Shines at The Smarter E Europe 2026 with Full-Ecosystem Offerings and AI-Driven Booth Experience
MUNICH, June 26, 2026 /PRNewswire/ -- Fox ESS, a global leader in renewable energy solutions, delivered a standout presence at The Smarter E Europe 2026. Making its European debut, the company unveiled a dynamic rebrand zone centered on its beloved mascot Maimai, offering interactive brand moment...
Yili Unveils AI-Powered Comic Series to Bring Dairy Supply Chain to Life at China Chain Expo
BEIJING, June 24, 2026 /PRNewswire/ -- Yili,
HDC 2026 Global Eco Summit: Huawei Ecosystem Fuels Partners' Growth in China and Cross-Border Success
DONGGUAN, China, June 19, 2026 /PRNewswire/ -- At the HDC 2026 Global Eco
Summit in Dongguan, Huawei convened global partners to explore how its
innovative technologies are reshaping digital interaction and business growth.
Revolutionizing Cancer Treatment: MAaGI Medical's "i" Series Multimodal Tumor Therapy Technique Globally Debuted
SHANGHAI, June 15, 2026 /PRNewswire/ -- In the summer of Suzhou, a distinguished gathering of eminent professionals convened. From June 11 to 14, 2026, the 20th Annual Scientific Meeting of the Asia Pacific Society of Cardiovascular and Interventional Radiology (APSCVIR 2026) was ceremoniously h...
CS2009 (PD-1/VEGF/CTLA-4 Trispecific Antibody) ASCO 2026 Key Highlights
SUZHOU, China, June 11, 2026 /PRNewswire/ -- The clinical datasets presented at ASCO 2026by CStone further validate the trispecific synergistic mechanism of CS2009 and support its potential to become a next-generation immuno-oncology (I/O) backbone therapy. I. Trispecific Design Rationale and Di...
OriCell's GPC3 CAR-T Receives NMPA Clearance for Confirmatory Phase II Trial in Late-Line Advanced Hepatocellular Carcinoma
SHANGHAI, June 7, 2026 /PRNewswire/ -- OriCell Therapeutics Holdings Limited ( The "Company" or "Oricell") ,announced that its proprietary GPC3-targeted autologous CAR-T therapy, Ori-C101, has received clearance from China's National Medical Products Administration (NMPA) to proceed into a confir...
Fox ESS Unveils Dynamic Energy Ecosystem Alongside Its First Rebrand Area at SNEC 2026
SHANGHAI, June 6, 2026 /PRNewswire/ -- Fox ESS, a global leader in renewable energy solutions, successfully concluded SNEC 2026 following the official launch of its refreshed brand identity. Across the three-day event, Fox ESS showcased a full-scale product portfolio, including residential and co...
Kelun-Biotech Presents First-in-human Study Data for Its Novel B7-H3 ADC SKB500 at ASCO 2026
CHENGDU, China, June 3, 2026 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", 6990.HK) announced that at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting held in Chicago, USA, the first-in-human study results of the novel B7...
Early Data Show Highly Selective FGFR2 Inhibitor 3HP-2827 Active in Advanced CCA; Chinese Academy of Sciences' Zhou Jian Comments on Potential for Patients With FGFR2 Alterations
CHICAGO, June 2, 2026 /PRNewswire/ -- At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, 3H Pharmaceuticals released new clinical data for its wholly owned candidate, 3HP-2827. The ongoing study focuses on patients with advanced cholangiocarcinoma (CCA) and other solid tumor...
/C O R R E C T I O N -- Ranok Therapeutics/
In the news release, Ranok Therapeutics Announces Positive Interim Phase 1 Data Of Its KRAS G12D Inhibitor RNK08954 In Patients With KRAS G12D-Mutated Metastatic Non-Small Cell Lung Cancer Presented At ASCO 2026, issued 01-Jun-2026 by Ranok Therapeutics over PR Newswire, we are advised by the co...
Hengrui Pharma Presents More Than 90 Oncology Studies at ASCO 2026, Highlighting Progress Across Multiple Tumor Types
SHANGHAI, June 1, 2026 /PRNewswire/ -- The 2026 American Society of Clinical Oncology (ASCO) Annual Meeting was held in Chicago from May 29 to June 2 (local time). As one of the world's leading oncology conferences, the ASCO Annual Meeting serves as a key venue for presenting advances in cancer r...
Minghui Pharmaceutical and Qilu Pharmaceutical Co-Announces Updated Clinical Data of MHB088C (QLC5508) from Phase I/II study in Heavily Pretreated mCRPC Patients at 2026 ASCO Annual Meeting
HANGZHOU and SHANGHAI, China, June 1, 2026 /PRNewswire/ -- Minghui Pharmaceutical ("Minghui"), a late-stage clinical biopharmaceutical company focused on developing innovative therapies for oncology and autoimmune diseases, todayannounced updated clinical data from its Phase I/II study evaluating ...
ASCO 2026 | Oricell's GPC3 CAR-T Ori-C101 Hits 66.7% ORR in Late-Line HCC, Signaling Best-in-Class Potential
CHICAGO, May 31, 2026 /PRNewswire/ -- Oricell Therapeutics, a clinical-stage biotech company pioneering cancer immunotherapy, today announced that its lead asset, Ori-C101, a GPC3-targeted CAR-T therapy, achieved a 66.7% objective response rate (ORR) in patients with Late-line refractory hepatoce...
Long-term Follow-up Results of CARsgen's Satri-cel as Sequential Therapy After First-Line Treatment for Gastric Cancer Presented at the 2026 ASCO Annual Meeting
SHANGHAI, May 31, 2026 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announces that the long-term analysis results of satricabtagene autoleucel ("satri-cel", CT041) (an autologous CAR T-cell product ca...
ASCO 2026 | CStone Presents Updated Clinical Data for CS2009 (PD-1/VEGF/CTLA-4 Trispecific Antibody), Reinforcing Triple-Target Synergy and Delivering Strong Proof-of-Concept
First-line NSCLC – Compelling Activity Across All PD-L1 Subgroups In first-line non-small cell lung cancer (NSCLC) patients with high PD-L1 expression (TPS ≥50%), CS2009 monotherapy achieved anobjective response rate (ORR) of 81.3% and a disease control rate (DCR) of 100.0%, with consistent benef...
D3 Bio Presents First-Line Data for Elisrasib (D3S-001) at ASCO 2026; Next-Generation KRAS G12C Inhibitor Shows Landmark Efficacy in Untreated NSCLC
Elisrasib monotherapy delivers an ORR of 78.0% and median PFS of 12.4 months in first-line KRAS G12C–mutant NSCLC (n=41) across all PD-L1 expression levels Combination of elisrasib with pembrolizumab achieves an ORR of 81.3% in first-line KRAS G12C–mutant NSCLC (n=48) across all PD-L1 expression ...
Week's Top Stories
Most Reposted
DBS crowned Southeast Asia's most valuable brand in Kantar BrandZ 2026 ranking
[Picked up by 305 media titles]
2026-07-15 12:00
Visa Reimagines Visa Infinite for Asia Pacific's Modern Affluent
[Picked up by 302 media titles]
2026-07-16 10:00
Gnomey Hollows Opens at PARKROYAL COLLECTION Marina Bay, Singapore, Extending the Hotel's Gnome-Themed Family Experience
[Picked up by 290 media titles]
2026-07-13 11:42
Tetra Pak Introduces Industry-first Carton Packaging for Shelf-stable Tuna to Support Southeast Asia's Growing Tuna Industry
[Picked up by 287 media titles]
2026-07-13 10:00
Klook signs an expanded two-year partnership with Korea Tourism Organization
[Picked up by 286 media titles]
2026-07-16 17:49
Most Read
PTCL Group Leadership Meets FinVolution at MWC Shanghai 2026 to Explore Credit Technology for Financial Inclusion in Pakistan
[Official Launch] AGONG Durian Uses Blockchain to Authenticate Every Musang King
![[Official Launch] AGONG Durian Uses Blockchain to Authenticate Every Musang King](https://mma.prnasia.com/media2/3005680/image1.jpg?p=medium600)
NYSE Content Update: Madrona Highlights Private Companies Building AI Apps
Former INTERPOL President H.E. Ahmed Naser Al-Raisi Joins Robo.ai as Chairman of Neurovia AI to Build Trusted, Sovereign AI Infrastructure in the UAE and GCC Region
Visa Reimagines Visa Infinite for Asia Pacific's Modern Affluent